Nov. 1, 2012
/PRNewswire/ -- Cartagenia, the world leader in providing genetic labs and clinicians software-based workflow support for variant assessment, lab reporting, and integration of diagnostic knowledge-bases, announced today that it has signed a license agreement for the Cartagenia BENCH
CNV platform with CombiMatrix Corporation (Nasdaq: CBMX), a molecular diagnostics company.
-based CombiMatrix is a CLIA-certified and CAP-accredited, publicly-owned commercial clinical laboratory offering DNA-based genomic testing services in the areas of prenatal and pediatric developmental disorders and oncology. CombiMatrix has established itself as an industry leader in microarray-based clinical testing via a core team of microarray-pioneering physicians, scientists and technicians and has a strong commitment to both client and patient-focused service.
BENCH will be used for the analysis, interpretation and reporting of microarray results in routine postnatal and prenatal settings. The flexible nature of the BENCH platform will allow it to be tailored to CombiMatrix's variant assessment and reporting workflow, significantly accelerating the interpretation and reporting process without disrupting the established operating procedures. Additionally, BENCH's architecture will allow integration and communication with existing IT systems at CombiMatrix.
Richard D. Hockett, Jr.
, M.D.,Chief Medical Officer at CombiMatrix remarked, "With our lab operations and test volumes growing, it made perfect sense to select the Cartagenia BENCH platform at this time. We already perform hundreds of microarray analyses per month and having recently expanded testing for the prenatal marketplace, that number will grow even more. The automation provided by BENCH
CNV gives us the ability to grow our array throughput while providing significant savings in both analysis and interpretation time and staffing. Another deciding factor was that Cartagenia clearly positions its solutions for clinical use in contrast to other software packages."
"We are pleased and excited to be working with CombiMatrix," said
, Cartagenia's VP of Sales,
. "Its selection of the BENCH platform is a strong validation of our approach and indicative of the efficiencies that BENCH can bring to diagnostic laboratories."
Cartagenia successfully went through the process of implementing an ISO-certified quality management system and has registered the BENCH platform for variant interpretation and reporting as a Class 1 Medical Device with the FDA.